



DESIGNING OF ANTI-CANCEROUS HISTONE DEACETYLASE INHIBITORS THROUGH 
MIMICKING OF PROTEIN-PROTEIN INTERFACES 
Original Article 
 
K. RAJAGANAPATHY1, R. SATHIYASUNDAR1, G. RAMESH KUMAR2, V. K. KALAICHELVAN1* 
1Department of Pharmacy, Annamalai University, Annamalai Nagar 608002, 2Department of Bioinformatics, AU-KBC Research Center, 
MIT, Anna University, Chromepet, Chennai 600044. 
Email: vkkalaichelvan@yahoo.co.in  
Received: 21 Aug 2014 Revised and Accepted: 20 Sep 2014 
ABSTRACT 
Objective: The objective of the study was to come up with of the small molecular modulators that inhibit protein – protein interfaces or 
interaction site in HDAC complexes. The main focus is on the mimicking or forming of tiny molecule wherever by inhibiting the protein-protein 
interactions in specifically HDAC protein complexes.  
Methods: By mimicking of the interface of the protein interaction site like SIN3A-SMRT complex as well as SIN3A-NcoR complexes. 
Results: Totally 10 molecular structures were designed through molecular docking with HDAC2 PDB Id 3MAX and were downloaded from protein 
data bank. 
Conclusion: The results clearly indicate that before synthesis and biochemical testing of new lead and its analogs; one can use molecular modeling 
based methods for qualitative assessment. 
Keywords: HDAC, SIN3-NcoR, Docking and protein-protein interfaces. 
 
INTRODUCTION 
Nucleosomes are the elemental units of chromatin and area 
unit comprised of a histone protein octamer around that 146 base 
pairs of deoxyribonucleic acid are wound. The octamer contains two 
copies of the four core histones: H2A, H2B, H3 and H4. 
Linker histones clamp entry and exit sites of deoxyribonucleic 
acid round the core histone octamer and, with different nuclear 
proteins, contribute to the formation of a condensed higher 
order chromatin structure (1). Core and linker histones are the 
foremost regulators of chromatin condensation, so their 
modifications regulate the structural stability of the Chromatin fiber. 
The orderly packing of eukaryotic deoxyribonucleic acid depends 
on enzymatic modification of histones by the covalent addition 
of methyl, acetyl group or phosphate teams to extend or decrease 
transcription. These epigenetic changes 
(mitotically hereditary alterations in gene expression that don't 
seem to be caused by changes within the deoxyribonucleic 
acid sequence) observed because the “histone code” influence 
chromatin structure and so regulate the accessibility of transcription 
factors to deoxyribonucleic acid. Histone acetylation results in 
chromatin de-condensation and increased transcription of the gene. 
This is accomplished by 2 enzymes known as HAT and HDAC 
enzymes alter the four core Histone proteins via acetylation and 
deacetylation at specific lysine (K) residues in the N-terminal tail of 
the histones in the nucleus [2,3]. HAT and HDACs are present 
together at transcriptionally active genes. While the HDACs are 
involved in the transcriptional repression and removal of acetyl 
groups from histones to cause condensation of chromatin, the HATs 
are involved in acetylation and de-condensation of the chromatin 
resulting in increased gene transcription. Thus, HDACs possess 
negative regulatory mechanisms to that of the HATs. Protein-protein 
interactions are exclusively changed or deregulated in cancer cells.  
There are four HDAC classes with several different HDACs in each 
class. Class I HDACs are homologous to yeast Rpd3 and include 
HDACs 1, 2, 3 and 8. Class I HDACs are expressed ubiquitously in 
human cell lines and tissues and are found primarily in the nucleus. 
Class II HDACs are homologous to yeast Hda1 and can be subdivided 
into two subclasses: ClassIIa (HDAC 4, 7, and9) and ClassIIb (HDAC 6 
and 10). Class II HDACs exhibit tissue-specific expressions and can 
shuttle between the nucleus and cytoplasm. Class I and II HDACs 
share homology in their catalytic sites. Class III HDACs or sirtuins 
(SIRT1-7) include a group of proteins that are homologous with the 
yeast Sir2 family of proteins. Class IV HDACs contain HDAC11 and 
are homologous with both classes I and II. The role of HDACs is not 
restricted to their contribution to histone deacetylation; they also 
play a role in the de acetylation of non-histone proteins. HDACs are 
key elements in the regulation of gene expression, differentiation 
and development, and the maintenance of cellular homeostasis [4]. 
HDAC2 is gift within the nucleus of human cells. it's concerned in 
transcriptional repression regulated by the retinoblastoma 
protein Rb and is recruited to deoxyribonucleic acid through 
interaction with transcription factors and nuclear receptors. 
HDAC2 is additionally found in giant multi-protein 
complexes known as co-repressor complexes that are recruited to 
promoters of genes by specific transcription factors to silence gene 
activity. HDAC2 is one among the histone-modifying enzymes that 
regulates gene expression by transforming chromatin structure and 
is gift within the Sin3A and nucleosome remodeling and de acetylase 
(NuRD) co-repressor complexes (5, 6). 
A very important feature of HDAC is that it needs many elements of 
different multi-protein complexes to perform its cellular activities. 
This includes transcriptional co-repressors like mSin3A, N-CoR/ 
SMRT–SIN3–HDACadvanced, PML and others in AML (7, 8). The 
SIN3–HDAC could be a ubiquitous, abundant and enormous 
macromolecule advanced with extremely preserved useful domains. 
The advanced contains HDAC-1, HDAC-2 and also the system 
macromolecule SIN3, and is concerned to influence many key 
restrictive signals. The N-CoR / area unit bridging proteins 
discharged by RAR together with SIN3-HDAC advanced. The N-
CoR/SMRTs act as a linker for the interaction of RAR-RXR with SIN3-
HDAC advanced is a. The RAR- a part of the nuclear hormone 
receptor family that functions as a transcription issue by binding to 
deoxyribonucleic acid and regulation transcription of its target 
genes. Where as the carboxyl terminal of the N-CoR /SMRT is to 
blame for non-redundant external interactions, the amino terminal 
mediates active transcriptional repression by mediating repression 
pathways in Acute Promyelocytic leukemia (APL) and Acute 
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Myelogenous leukemia (AML). Upon binding of ligand RA to its 
receptor, the N-CoR–SIN3–HDAC co-repressor advanced is 
discharged and changed for the binding of a co-activator advanced 
like TIF2–CBP HAT and factor transcription is activated and is covert 
within the absence of ligand [9]. 
Objective 
The objective of the study has been coming up with of the small 
molecular modulators that inhibit protein – protein interfaces or 
interaction site in HDAC complexes. One protein combines with 
another protein and forms protein-protein interactions and 
produce protein complexes. Our aim is to produce (mimic) a 
small molecule about protein interfaces and reacting the molecule 
with macromolecule (protein) complexes wherever by inhibiting the 
protein-protein interactions. The main focus is on the mimicking or 
forming of tiny molecule wherever by inhibiting the protein-protein 
interactions in specifically HDAC protein complexes.  
Experimentation  
The discovery of small molecules that regulate protein–protein 
binding interactions in designing a new molecule and its practical 
importance. Accordingly, the prevailing approaches have been 
structure-based design and combinatorial methods (selection or 
screening of libraries). Often, design is aimed at mimicking peptide 
or protein structural elements in a smaller form. A successful design 
may then become the scaffold for a combinatorial library. 
Combinatorial method, on the other hand, allows quick evaluation of 
many possible ligands and frequently yields unexpected solutions. 
These may be structurally characterized and used as templates for 
further design. In addition, previous reports have appeared 
describing particular protein–protein interactions that can be 
inhibited by small molecules or by very short peptides. 
Prediction of protein complexes 
Patch Dock is an algorithm for molecular protein-protein docking. 
The input is two molecules of any type: proteins, DNA, peptides, 
drugs. The output is a list of potential complexes sorted by shape 
complementarily criteria. In order to mimic the SIN3A-SMRT 
complex as well as SIN3A-NcoR complexes, the 3D crystal structures 
of proteins: NCoR (PDB ID: 1xc5), SIN3A (PDB ID: 1G1E) and SMRT 
(PDB ID: 2ODD) were retrieved from the Protein Data Bank (PDB). 
First, the SIN3A-NcoR complex was mimicked by docking SIN3A and 
NcoR using PatchDock (10-12). Similarly, the SIN3A-SMRT complex 
was mimicked by docking with the SIN3A and SMRT to obtain a 
mimicked two protein complex structure SIN3A-NcoR and SIN3A-
SMRT complexes). 
 
Table 1: Proteins interacting with Sin3 have a wide range of functions. For those characterized, most commonly interact with anα-helix in 
PAH pocket. 
Factor Functions SIN3 Interacting domain SIN3 Interfaces 




SMRT Co-repressor for nuclear hormone receptors Extensive (SIN3A only) 
The above table has shown the Sin3 complex interfaces such as PAH1, mSIN3A, mSIN3B and PAH2 which are scaffolding proteins and are 
interacting with seven factors. Among the seven factors which are mention in that table no-1, only two factors have been selected for protein-
protein docking or prediction of protein complexes. And this protein-protein interactions to carry out with patchdock. 
 
 
Fig. 1: Docked Structure of SIN3A PAH2 domain complexed with 
SMRT viewed by Argus lab 
 
 
Fig. 2: Docked structure of mSin3A PAH1 domain complexed 
with N-CoR viewed by arguslab 
Prediction of protein-protein interfaces: mimics and ligand 
design 
Protein-Protein interfaces or interaction sites were predicted the 
small molecules were designed which has similar structure as 
protein-protein interfaces by using the online tool metappisp (A 
Meta server for protein-protein interaction site prediction). The 
obtained 3D complexes SIN3A- SMRT and SIN3A-NcoR was 
introduced to the online metta-PPISP server for the prediction of 
protein-protein interface region.  
The interface region were interpreted and analyzed by Swiss PDB 
Viewer. The possible small molecule structures that mimic the 
interface region were identified and obtained structures were drawn 
by using Marvin Sketch. Marvin Sketch has advanced chemical editor 
for drawing chemical structures and it has a rich list of editing 
features.  
 
Table 2: Selected protein-protein interface region 
S. No Interface ID Interface Region 
1. Ligand -1 PHE, GLU. 
2. Ligand -2 TYR, GLN. 
3. Ligand -3 PRO, ASP, ALA. 
4. Ligand -4 TYR, TYR, LEU. 
5. Ligand -5 LYS, LYS. 
 
Chemical substituent analog of the novel lead molecules 
The five newly designed lead molecules of the drugs were created by 
replacing the hydrophilic region on the target molecule with other 
functional groups (considered at random). Five analogues of the 
small molecule of the newly designed lead molecules has been 
studied by performing various molecular properties calculation, 
ADME as well as protein-ligand interactions. 
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Fig. 3: Novel Lead Molecules of Mimicked Protein-protein 
Interfaces 
 























5. Ligand-4 COOH  NH-OH-CO-CH2-Cl (R1) 





RESULT AND DISCUSSION  
Molecular docking study 
A molecular docking study by Schrodinger-Maestro 9.3.5 Version 
was performed to calculate of binding energy and H-bond 
interaction, H-bond donor & acceptors, hydrobhobicity and 
lipobobicity at the active site for all the newly designed small 
molecules and its chemical substituted analogues, totally 10 
molecular structures were separately docked with HDAC2 PDB Id 
3MAX were downloaded from protein data bank. 
 
Fig. 4: Chemical substituted Analogues Of the Novel Lead Molecules 
 
Table 3: Docking Result 
S. No. Ligand(small molecule) Docking Score Ebind 
(MM) 
1. Ligand - 2 -10.9 
2. Ligand - 5 -10.6 
3. Ligand - 4 -10.0 
4.  Ligand – 4 a -9.8 
5. Ligand - 5a -9.6 
6. Ligand -1 -9.5 
7. Ligand - 3 -8.3 
 
  
Fig. A Fig. B 
  
Fig. C Fig. D 
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Fig. E Fig. F 
Fig. 5: Fig-a, b, c, d, e, f Showing Most active Protein –Ligand interactions of Ligand No-1,2,4,4a,5,5a. 
 
ADME analysis 
Present study identify through docking and binding interactions of 
various novel lead molecules (As similar to Protein-Protein 
Interfaces) and its analogues for anti-cancerous histone deacetylase 
inhibitors. After analyzing of the molecular docking and ADME (By 
using qikprop command in Maestro) the ligand no 1, 2, 4, 4a, 5, 5a 
showing most active binding energy of the targeted protein and its 
obeying good Lipinski rule of five and ADME test and results are 
shown. and its showing more than seven hydrogen bond 
interactions and its including π - π stacking, hydrogen bond (side 
chain and backbone) and metal ion (zing binding motif) interactions.
 
Table 9: ADME analysis 
S. No Ligand Mol. wt VD (L) FA(%) Coca2-permeability(cm/s) Log p Rotable bond 
1. Ligand-1 278.307 955.142 128.831 7E-05 1.2 11 
2. Ligand-2 349.386 1158.789 220.261 2E-06 -1 14 
3. Ligand-3 293.322 974.936 142.448 9E-08 -2.7 12 
4. Ligand-4 365.385 1179.198 231.229 2E-05 0.8 18 
5. Ligand-5 301.299 953.796 288.915 3E-05 2.6 18 
6. Ligand-1a 387.389 1192.889 424.07 4E-06 -1.3 18 
7. Ligand-2a 457.525 1460.759 240.084 2E-05 0.5 10 
8. Ligand-3a 530.577 1631.824 274.511 9E-08 -2.6 14 
9. Ligand-4a 274.362 988.378 284.704 6E-08 -3.3 18 
10 Ligand-5a 374.364 1245.106 404.902 4E-07 -1.7 20 
 
Predicted properties 
• Fraction of oral dose absorbed (FA) 
• Caco-2 permeability 
• Volume of distribution (VD) 
• Octanol/water distribution coefficient (LogP) 
 
Table 10: The result of analysis ADME continue 
Small molecule 
ID 
S. A. A 
(A2) 











Ligand-1 526.2 632.1 1198.34 -5.67 92.43 52.23 3 5 
Ligand-2 546.41 620.03 1090.59 -5.53 88.65 33.75 4 8 
Ligand-3 485.3 578.8 976.6 -16.41 82.76 33.31 5 8 
Ligand-4 575.8 698.7 1305.7 -17.48 136.1 51.1 8 10 
Ligand-5 630.9 652.8 1057.4 -18.7 82.2 32.8 6 9 
Ligand-1a 654.8 673.8 1176.4 -5.57 108.5 41.7 3 6 
Ligand-2a 602.8 671.9 1126.3 -22.45 93.7 37.6 5 9 
Ligand-3a 552.5 623.8 1066.4 -34.6 88.6 36.3 7 11 
Ligand-4a 692.5 771.7 1377.3 -21.15 123.5 49.2 4 10 
Ligand-5a 618.08 624.2 1028.6 -11.49 83.5 31.03 5 9 
 
Predicted properties 
• S. S. A: - Surface area approximate 
• S. S. G: - Surface area grid 
• Vol: - Volume 
• Hyd. ener: - Hydration energy 
• Ref: - Refractivity 
• Polari: - Polarizibility 
• Drs: - Hydrogen bond donars 
• Ars: - Hydrogen bond acceptors 
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These results clearly indicate that before synthesis and biochemical 
testing of new lead and its analogs; one can use molecular modeling 
based methods for qualitative assessment of relative binding 
affinities for speeding up drug discovery process by eliminating less 
potent compounds from synthesis. The ligand No 1,2,4,4a,5,5a is a 
new lead and analogue for the anti-cancerous histone deacetylase 
inhibitor for disruption of HDAC2.  
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